688193 仁度生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.5451.105-0.8330.8583.736
总资产报酬率 ROA (%)0.5061.017-0.7630.7713.180
投入资产回报率 ROIC (%)0.5391.090-0.8220.8443.639

边际利润分析
销售毛利率 (%)76.20678.04179.48781.25665.529
营业利润率 (%)13.7236.437-8.2243.3109.053
息税前利润/营业总收入 (%)13.0615.543-12.093-2.0537.333
净利润/营业总收入 (%)11.8726.229-4.4055.0247.679

收益指标分析
经营活动净收益/利润总额(%)37.953-177.09280.414-375.33150.140
价值变动净收益/利润总额(%)66.551134.365-71.851159.27634.935
营业外收支净额/利润总额(%)-5.564-2.0064.182-14.271-3.094

偿债能力分析
流动比率 (X)14.97312.91311.88911.46210.188
速动比率 (X)14.64112.60511.55211.0979.892
资产负债率 (%)6.6517.7028.2958.72011.696
带息债务/全部投入资本 (%)0.2800.5810.562-0.095-1.251
股东权益/带息债务 (%)35,335.98216,964.87417,544.316-104,367.986-7,834.932
股东权益/负债合计 (%)1,403.5571,198.4151,105.5901,046.754754.992
利息保障倍数 (X)213.448-7.2273.4450.415-5.064

营运能力分析
应收账款周转天数 (天)99.792104.657128.061198.89394.892
存货周转天数 (天)184.123234.722265.854332.26281.934